109 related articles for article (PubMed ID: 27824060)
1. Cost-effectiveness Analysis of Fluorouracil, Leucovorin, and Irinotecan versus Epirubicin, Cisplatin, and Capecitabine in Patients with Advanced Gastric Adenocarcinoma.
Wen F; Zheng H; Wu Y; Wheeler J; Zeng X; Fu P; Li Q
Sci Rep; 2016 Nov; 6():36060. PubMed ID: 27824060
[TBL] [Abstract][Full Text] [Related]
2. Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Fédération Francophone de Cancérologie Digestive, Fédération Nationale des Centres de Lutte Contre le Cancer, and Groupe Coopérateur Multidisciplinaire en Oncologie) study.
Guimbaud R; Louvet C; Ries P; Ychou M; Maillard E; André T; Gornet JM; Aparicio T; Nguyen S; Azzedine A; Etienne PL; Boucher E; Rebischung C; Hammel P; Rougier P; Bedenne L; Bouché O
J Clin Oncol; 2014 Nov; 32(31):3520-6. PubMed ID: 25287828
[TBL] [Abstract][Full Text] [Related]
3. Trastuzumab for the treatment of HER2-positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction.
Norman G; Rice S; Spackman E; Stirk L; Danso-Appiah A; Suh D; Palmer S; Eastwood A
Health Technol Assess; 2011 May; 15 Suppl 1():33-42. PubMed ID: 21609651
[TBL] [Abstract][Full Text] [Related]
4. Prognostic factors in patients treated with second-line chemotherapy for advanced gastric cancer: results from the randomized prospective phase III FFCD-0307 trial.
Touchefeu Y; Guimbaud R; Louvet C; Dahan L; Samalin E; Barbier E; Le Malicot K; Cohen R; Gornet JM; Aparicio T; Nguyen S; Azzedine A; Etienne PL; Phelip JM; Hammel P; Chapelle N; Sefrioui D; Mineur L; Lepage C; Bouche O
Gastric Cancer; 2019 May; 22(3):577-586. PubMed ID: 30311042
[TBL] [Abstract][Full Text] [Related]
5. A randomised phase II study of combination chemotherapy with epirubicin, cisplatin and capecitabine (ECX) or cisplatin and capecitabine (CX) in advanced gastric cancer.
Yun J; Lee J; Park SH; Park JO; Park YS; Lim HY; Kang WK
Eur J Cancer; 2010 Mar; 46(5):885-91. PubMed ID: 20060288
[TBL] [Abstract][Full Text] [Related]
6. Docetaxel/cisplatin followed by FOLFIRI versus the reverse sequence in metastatic gastric cancer.
Kim JA; Lee J; Han B; Park SH; Park JO; Park YS; Lim HY; Kang WK
Cancer Chemother Pharmacol; 2011 Jul; 68(1):177-84. PubMed ID: 20878159
[TBL] [Abstract][Full Text] [Related]
7. Economic evaluation of FLOT and ECF/ECX perioperative chemotherapy in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma.
Zeng H; Wang C; Song LY; Jia SJ; Zeng X; Liu Q
BMJ Open; 2022 Nov; 12(11):e060983. PubMed ID: 36375981
[TBL] [Abstract][Full Text] [Related]
8. Patient-based cost-effectiveness analysis of FOLFIRI versus FOLFOX7 for advanced gastric adenocarcinoma in China: A 4-year prospective randomised phase II study.
Wen F; Zheng H; Zhang P; Zhou J; Chen H; Zhou K; Li Q; Bi F
Eur J Cancer Care (Engl); 2020 Jan; 29(1):e13196. PubMed ID: 31825141
[TBL] [Abstract][Full Text] [Related]
9. Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study.
Iveson T; Donehower RC; Davidenko I; Tjulandin S; Deptala A; Harrison M; Nirni S; Lakshmaiah K; Thomas A; Jiang Y; Zhu M; Tang R; Anderson A; Dubey S; Oliner KS; Loh E
Lancet Oncol; 2014 Aug; 15(9):1007-18. PubMed ID: 24965569
[TBL] [Abstract][Full Text] [Related]
10. Effect of perioperative FLOT versus ECF/ECX on short-term outcomes after surgery for resectable oesophagogastric adenocarcinoma: propensity score-matched study.
Moussa O; Bhogal RH; Malietzis G; Fribbens C; Starling N; Gerlinger M; Watkins D; Chau I; Rao S; Cunningham D; Allum WH; Chaudry A; Kumar S
BJS Open; 2022 Jan; 6(1):. PubMed ID: 35195263
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness analysis of capecitabine monotherapy versus capecitabine plus oxaliplatin in elderly patients with advanced gastric cancer.
Peng J; Tan C; Zeng X; Liu S
PLoS One; 2018; 13(6):e0199553. PubMed ID: 29953476
[TBL] [Abstract][Full Text] [Related]
12. Capecitabine for the treatment of advanced gastric cancer.
Norman G; Soares M; Peura P; Rice S; Suh D; Wright K; Sculpher M; Eastwood A
Health Technol Assess; 2010 Oct; 14(Suppl. 2):11-7. PubMed ID: 21047486
[TBL] [Abstract][Full Text] [Related]
13. Randomized prospective phase II study to compare the combination chemotherapy regimen epirubicin, cisplatin, and 5-fluorouracil with epirubicin, cisplatin, and capecitabine in patients with advanced or metastatic gastric cancer.
Ocvirk J; Reberšek M; Skof E; Hlebanja Z; Boc M
Am J Clin Oncol; 2012 Jun; 35(3):237-41. PubMed ID: 21399488
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizumab plus capecitabine plus irinotecan (FNCLCC ACCORD 13/0503 study).
Ducreux M; Adenis A; Pignon JP; François E; Chauffert B; Ichanté JL; Boucher E; Ychou M; Pierga JY; Montoto-Grillot C; Conroy T
Eur J Cancer; 2013 Apr; 49(6):1236-45. PubMed ID: 23352604
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and cost-effectiveness of second-line chemotherapy in elderly patients with advanced gastric cancer.
Zhou K; Wen F; Zhang P; Zhou J; Chen H; Zheng H; Yang Y; Li Q
Clin Transl Oncol; 2017 Sep; 19(9):1117-1124. PubMed ID: 28353006
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the relevance of the growth modulation index (GMI) from the FFCD 0307 randomized phase III trial comparing the sequence of two chemotherapeutic regimens.
du Rusquec P; Guimbaud R; Le Malicot K; Gornet JM; Nguyen S; Lecomte T; Khemissa-Akouz F; Perrier H; Bouché O; Paoletti X; Le Tourneau C
ESMO Open; 2023 Aug; 8(4):101616. PubMed ID: 37542912
[TBL] [Abstract][Full Text] [Related]
17. A randomized phase II trial of pemetrexed plus irinotecan (ALIRI) versus leucovorin-modulated 5-FU plus irinotecan (FOLFIRI) in first-line treatment of locally advanced or metastatic colorectal cancer.
Underhill C; Goldstein D; Gorbounova VA; Biakhov MY; Bazin IS; Granov DA; Hossain AM; Blatter J; Kaiser C; Ma D
Oncology; 2007; 73(1-2):9-20. PubMed ID: 18334829
[TBL] [Abstract][Full Text] [Related]
18. Feasibility of sequential therapy with FOLFIRI followed by docetaxel/cisplatin in patients with radically resected gastric adenocarcinoma. A randomized phase III trial.
Di Bartolomeo M; Buzzoni R; Mariani L; Ferrario E; Katia D; Gevorgyan A; Zilembo N; Bordonaro R; Bochicchio AM; Massidda B; Ardizzoia A; Marini G; Aitini E; Schieppati G; Comella G; Pinotti G; Palazzo S; Cicero G; Bajetta E; ; Villa E; Fagnani D; Reguzzoni G; Agostana B; Oliani C; Kildani B; Duro M; Botta M; Mozzana R; Mantovani G
Oncology; 2006; 71(5-6):341-6. PubMed ID: 17855795
[TBL] [Abstract][Full Text] [Related]
19. The efficacy and toxicity of irinotecan with leucovorin and bolus and continuous infusional 5-fluorouracil (FOLFIRI) as salvage therapy for patients with advanced gastric cancer previously treated with platinum and taxane-based chemotherapy regimens.
Kaya AO; Coskun U; Gumus M; Dane F; Ozkan M; Isıkdogan A; Alkis N; Buyukberber S; Yumuk F; Budakoglu B; Demirci U; Berk V; Bilici A; Inal A; Arpacı E; Benekli M;
J Chemother; 2012 Aug; 24(4):217-20. PubMed ID: 23040686
[TBL] [Abstract][Full Text] [Related]
20. Cost-Effectiveness Analysis of Different Sequences of the Use of Epidermal Growth Factor Receptor Inhibitors for Wild-Type KRAS Unresectable Metastatic Colorectal Cancer.
Riesco-Martínez MC; Berry SR; Ko YJ; Mittmann N; Giotis A; Lien K; Wong WW; Chan KK
J Oncol Pract; 2016 Jun; 12(6):e710-23. PubMed ID: 27143148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]